Seelos Therapeutics, Inc. - Company Profile
Powered by 
All the data and insights you need on Seelos Therapeutics, Inc. in one report.
$295
- Save hours of research time and resources with
our up-to-date Seelos Therapeutics, Inc. Strategy Report
- Understand Seelos Therapeutics, Inc. position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Seelos Therapeutics, Inc. patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4337182A1 | Application | Verringerung der nebenwirkungen von nmda-rezeptor-antagonisten | A61K31/135; A61K31/137; A61K9/0043; A61P25/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/22; A61P25/24; A61P25/28 | March 20, 2024 |
| KR1020240024085A | Application | 부작용이 감소된 nmda 수용체 길항제 | A61K31/135; A61K31/137; A61K9/0043; A61P25/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/22; A61P25/24; A61P25/28 | February 23, 2024 |
| BR112023023272A2 | Application | Redução dos efeitos colaterais de antagonistas de receptor nmda | A61K31/135; A61K31/137; A61K9/0043; A61P25/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/22; A61P25/24; A61P25/28 | January 30, 2024 |
| US20240025953A1 | Application | Compositions and methods for inhibiting alpha-synuclein aggregation | C12N15/86; C12N2750/14143; C12N2830/15; C12N2830/60; A61K48/005; A61K48/0075; C07K14/47; C07K2319/42 | January 25, 2024 |
| US20240009113A1 | Application | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose | A61K31/7016; A61K9/0019; A61K9/08 | January 11, 2024 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer